506891300 09/27/2021 PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT6938121

SUBMISSION TYPE:		NEW ASSIGNMENT	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:		ASSIGNMENT	ASSIGNMENT		
	ΓΥ DATA				
		Name		Execution Date	
JUNO THERAPEU	TICS, INC.			07/27/2021	
RECEIVING PART	Υ DATA				
Name:	JUNO TI	JUNO THERAPEUTICS GMBH			
Street Address:	GRILLP	GRILLPARZERSTRASSE 10			
City:	MUNICH	MUNICH			
State/Country:	GERMAI	GERMANY			
Postal Code:	81675	81675			
PROPERTY NUMB	EBS Total: 1				
Property Type		Number			
Application Number: 166		6608796			
CORRESPONDEN	CE DATA				
Fax Number:	3)	58)720-5125			
Fax Number: <i>Correspondence v</i>) will be sent to a	he e-mail address first; if t			
Fax Number: Correspondence v using a fax numbe	(8 vill be sent to a er, if provided;	,			
Fax Number: <i>Correspondence v using a fax numbe</i> Phone:	(8 vill be sent to a er, if provided; 8	he e-mail address first; if t if that is unsuccessful, it w			
Fax Number: <i>Correspondence v using a fax numbe</i> Phone: Email:	({ vill be sent to a er, if provided; 8 jj	he e-mail address first; if t if that is unsuccessful, it w 583147634			
Fax Number: <i>Correspondence v using a fax numbe</i> Phone: Email: Correspondent Na) vill be sent to a er, if provided; 8 jji me: F	<i>he e-mail address first; if t if that is unsuccessful, it w</i> 583147634 ung@mofo.com	vill be sent via		
	({ vill be sent to a er, if provided; 8 jju me: F	<i>he e-mail address first; if t if that is unsuccessful, it w</i> 583147634 ung@mofo.com ACHEL RICE	r ill be sent via LP		
Fax Number: <i>Correspondence v using a fax numbe</i> Phone: Email: Correspondent Na Address Line 1:	({ vill be sent to a er, if provided; 8 jj me: F M 1	<i>he e-mail address first; if t</i> <i>if that is unsuccessful, it w</i> 583147634 ung@mofo.com ACHEL RICE ORRISON & FOERSTER, L	t ill be sent via LP SUITE 100		
Fax Number: <i>Correspondence v using a fax numbe</i> Phone: Email: Correspondent Na Address Line 1: Address Line 2:	({ vill be sent to a pr, if provided; 8 jju me: F 1 S	<i>he e-mail address first; if t</i> <i>if that is unsuccessful, it w</i> 583147634 ung@mofo.com ACHEL RICE IORRISON & FOERSTER, L 2531 HIGH BLUFF DRIVE, S	t ill be sent via LP SUITE 100		
Fax Number: <i>Correspondence v using a fax numbe</i> Phone: Email: Correspondent Na Address Line 1: Address Line 2: Address Line 4:	({ vill be sent to a er, if provided; 8 jju me: P M 1 S T NUMBER:	<i>he e-mail address first; if t</i> <i>if that is unsuccessful, it w</i> 583147634 ung@mofo.com ACHEL RICE ORRISON & FOERSTER, L 2531 HIGH BLUFF DRIVE, S AN DIEGO, CALIFORNIA 92	t ill be sent via LP SUITE 100		
Fax Number: <i>Correspondence v using a fax numbe</i> Phone: Email: Correspondent Na Address Line 1: Address Line 2: Address Line 4:	({ vill be sent to a er, if provided; 8 jju me: P M 1 S T NUMBER:	he e-mail address first; if t if that is unsuccessful, it w 583147634 ung@mofo.com ACHEL RICE ORRISON & FOERSTER, L 2531 HIGH BLUFF DRIVE, S AN DIEGO, CALIFORNIA 92 73504-20085.00	t ill be sent via LP SUITE 100		
Fax Number: Correspondence v using a fax number Phone: Email: Correspondent Na Address Line 1: Address Line 2: Address Line 4: ATTORNEY DOCKE	({ vill be sent to a er, if provided; 8 jju me: P M 1 S T NUMBER:	he e-mail address first; if t if that is unsuccessful, it w 583147634 ung@mofo.com ACHEL RICE ORRISON & FOERSTER, L 2531 HIGH BLUFF DRIVE, S AN DIEGO, CALIFORNIA 92 73504-20085.00 RACHEL RICE	t ill be sent via LP SUITE 100		

ASSIGNMENT

THIS ASSIGNMENT is by Juno Therapeutics, Inc., a corporation duly organized under and pursuant to the laws of Delaware and having its principal place of business at 400 Dexter Ave. N, Suite 1200, Seattle, Washington 98109-4703 (hereinafter referred to as the Assignor).

THIS ASSIGNMENT is to Juno Therapeutics GmbH, a corporation duly organized under and pursuant to the laws of Germany and having its principal place of business at Grillparzerstrasse 10, Munich, Germany 81675 (hereinafter referred to as the Assignee); and

WHEREAS, this Assignment relates to the invention entitled OLIGOMERIC PARTICLE REAGENTS AND METHODS OF USE THEREOF and set forth in United States patent application bearing Serial No. 16/608,796 and having a filing date of April 27, 2018 (Int'l); and

WHEREAS Assignee is desirous of acquiring the entire right, title and interest in and to said inventions and said application for letters patent in the United States of America, and in any United States, international and foreign applications for letters patent based thereon or claiming priority thereto, and in any United States or foreign letters patent or patents, to be obtained therefor and thereon:

NOW, THEREFORE, for good and sufficient consideration, the receipt of which is hereby acknowledged, and to the extent that the Assignor has not done so already via a prior agreement with the Assignee or a predecessor in interest of the Assignee, or if the Assignor has already dose so via a prior agreement with the Assignee or a predecessor in interest of the Assignee then in confirmation of any obligation to do so in said prior agreement,

1. Assignor hereby sells, assigns, transfers and sets over, unto said Assignee, its successors, legal representatives and assigns, Assignor's entire right title and interest in and to the abovementioned inventions, application for letters patent, any and all non-provisional applications for said inventions or that claim priority to said application, any and all divisions, continuations, continuations-in-part claiming priority thereto or the benefit thereof, substitutions of said applications, and any and all letters patent or patents granted in the United States of America and all foreign countries or jurisdictions which may be granted therefor and thereon, including, without limitation, any modifications to such letters patent or patents such as through reissue, reexamination or other post-grant proceeding, and any and all extensions of said letters patent or patents, and all rights under the International Convention for the Protection of Industrial Property, the same to be held and enjoyed by Assignee (including any right to institute actions and to recover damages for past, present and future infringement and any and all rights to claim priority to said application for letters patent and any and all applications claiming priority thereto or based on said inventions), for Assignee's own use and the use of its successors, legal representatives and assigns, to the full end of the term or terms for which letters patent or patents may be granted, as fully and entirely as the same would have been held and enjoyed by the Assignor, had this sale and assignment not been made.

2. Assignor hereby warrants and covenants (a) that, at the time of execution and delivery of this agreement, Assignor is the sole and lawful owner of Assignor's entire right, title and interest in and to said inventions and said application for letters patent, and that the same are unencumbered and that said Assignor has good and full right and lawful authority to sell and

convey the same in the manner herein set forth in this agreement, or (b) that Assignor solely and lawfully owned Assignor's entire right, title and interest in and to said inventions and said application for letters patent, and that the same were unencumbered and that Assignor previously sold, assigned, transferred and set over to Assignee and its successors, legal representatives and assigns, or to a predecessor in interest of Assignee, Assignor's entire right, title and interest in and to said inventions and said application for letters patent.

3. Assignor shall promptly sign and execute all papers and documents, take all lawful oaths, and do all acts necessary, required or useful for the procurement, maintenance, enforcement, defense or otherwise to secure title to the Assignee, at the sole cost and expense of Assignee, its successors, legal representatives and assigns, in each case including, without limitation, arising from or relating to (a) said inventions and said application for letters patent; (b) any and all non-provisional applications, divisions, continuations, continuations-in-part claiming priority thereto or the benefit thereof, or any substitution of any such application, or (c) any letters patent or patents for said invention in any country or jurisdiction, including, without limitation, any modifications to such letters patent or patents through any reissue, reexamination or other post-grant proceeding. To be clear, for purposes of this paragraph, "procurement, maintenance, enforcement, defense" shall include, without limitation, any preparation, prosecution, pre-grant proceeding, and post-grant proceeding, whether before a patent office or other administrative body or judicial body with jurisdiction therefor.

4. Assignor hereby authorizes and requests the Commissioner of Patents in the United States to issue the above mentioned letters patent or patents of the United States to Assignee as the assignee of said inventions and the letters patent or patents to be issued thereon, for the sole use of Assignee, its successors, legal representatives and assigns.

5. This assignment may be executed in one or more counterparts, with the same effect as if each signature were on the same document. Each counterpart so executed shall be deemed to be an original, and all such counterparts shall be construed together and shall constitute one agreement.

In witness whereby, executed by the undersigned on the date(s) opposite the undersigned name(s).

ASSIGNOR: Date: July 27, 2024

Signature: 7 Name=Denise Hickey

Title: Authorized Signatory/VP & Assistant General Counsel, Bristol-Myers Squibb Company Company: Juno Therapeutics, Inc.

ASSIGNEE:

Date: 21 July 2021

Signature: Name: Denise Hickey

Title: Authorized Signatory/VP & Assistant General Counsel, Bristol-Myers Squibb Company Company: Juno Therapeutics GmbH

sf-4381992

PATENT REEL: 057613 FRAME: 0225

RECORDED: 09/27/2021